Table 5.
Multivariate model based on accelerometry data for bouts defined as ≥3 METs per minute for a duration of ≥10 minutes.
| Model | Estimate | Standard Error | F-Value | P-value | R2 for Model |
|---|---|---|---|---|---|
| Dependent Variable: Bouts per Day | 0.0732 | ||||
| Age | 0.0001 | 0.0032 | 0.00 | 0.9688 | |
| BMI | 0.0006 | 0.0037 | 0.03 | 0.8690 | |
| Sex (Women versus Men) | −0.2999 | 0.0424 | 50.12 | <0.0001 | |
| Race/Ethnicity (White is the reference group) | 2.42 | 0.0644 | |||
| African-American/Black | −0.1075 | 0.0491 | |||
| Hispanic | 0.1033 | 0.0865 | |||
| Other/Mixed/Missing | −0.0702 | 0.1028 | |||
| Baseline Fitness (maximal METs) | 0.0696 | 0.0128 | 29.77 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.45 | 0.8108 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | −0.0138 | 0.0592 | |||
| Thiazolidinedione | −0.0274 | 0.0656 | |||
| Insulin Alone | −0.0075 | 0.1063 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | 0.0465 | 0.0872 | |||
| Insulin + Thiazolidinedione | 0.0725 | 0.0871 | |||
| Without Baseline history of CVD | 0.0511 | 0.0539 | 0.90 | 0.3425 | |
| Dependent Variable: Minutes per Bout * | 0.0814 | ||||
| Age | 0.0693 | 0.0406 | 2.91 | 0.0883 | |
| BMI | −0.0922 | 0.0485 | 3.62 | 0.0572 | |
| Sex (Women versus Men) | −0.2286 | 0.5368 | 0.18 | 0.6703 | |
| Race/Ethnicity (White is the reference group) | 1.88 | 0.1313 | |||
| African-American/Black | −1.4866 | 0.6439 | |||
| Hispanic | −0.8860 | 1.0659 | |||
| Other/Mixed/Missing | −0.4300 | 1.3418 | |||
| Baseline Fitness (maximal METs) | 0.8991 | 0.1617 | 53.69 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.52 | 0.7594 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | 0.1964 | 0.7466 | |||
| Thiazolidinedione | 0.6639 | 0.8297 | |||
| Insulin Alone | 1.4732 | 1.3991 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | −0.4743 | 1.0970 | |||
| Insulin + Thiazolidinedione | 0.0157 | 1.1096 | |||
| Without Baseline history of CVD | 0.4176 | 0.6987 | 0.36 | 0.5501 | |
| Dependent Variable: METs per Minute * | 0.1325 | ||||
| Age | 0.0047 | 0.0042 | 1.27 | 0.2602 | |
| BMI | 0.0082 | 0.0050 | 2.74 | 0.0982 | |
| Sex (Women versus Men) | 0.2109 | 0.0550 | 14.69 | 0.0001 | |
| Race/Ethnicity (White is the reference group) | 0.39 | 0.7591 | |||
| African-American/Black | −0.0636 | 0.0661 | |||
| Hispanic | −0.0574 | 0.1092 | |||
| Other/Mixed/Missing | −0.0537 | 0.1375 | |||
| Baseline Fitness (maximal METs) | 0.2105 | 0.0164 | 164.77 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 1.37 | 0.2315 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | 0.0650 | 0.0765 | |||
| Thiazolidinedione | 0.0044 | 0.0850 | |||
| Insulin Alone | 0.0476 | 0.1433 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | −0.0460 | 0.1124 | |||
| Insulin + Thiazolidinedione | 0.2341 | 0.1137 | |||
| Without Baseline history of CVD | −0.0075 | 0.0716 | 0.01 | 0.9171 | |
| Dependent Variable: MET-minutes * | 0.1095 | ||||
| Age | 0.5042 | 0.2898 | 3.03 | 0.0821 | |
| BMI | −0.3135 | 0.3455 | 0.82 | 0.3644 | |
| Sex (Women versus Men) | 3.5176 | 3.8293 | 0.84 | 0.3585 | |
| Race/Ethnicity (White is the reference group) | 1.29 | 0.2778 | |||
| African-American/Black | −8.9192 | 4.5984 | |||
| Hispanic | −2.7792 | 7.5975 | |||
| Other/Mixed/Missing | −4.4441 | 9.5646 | |||
| Baseline Fitness (maximal METs) | 101.45 | <0.0001 | |||
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.62 | 0.6836 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | 3.1416 | 5.3222 | |||
| Thiazolidinedione | 4.6801 | 5.9138 | |||
| Insulin Alone | 10.4050 | 9.9725 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | −4.1663 | 7.8196 | |||
| Insulin + Thiazolidinedione | 7.1660 | 7.9090 | |||
| Without Baseline history of CVD | 2.0723 | 4.9807 | 0.17 | 0.6774 |
*
Indicates that data represent participants who reported ≥1 bout during the observation period that met the criteria of ≥3 METs per minute and ≥10 minutes for that bout.